Literature DB >> 2834465

Immunology of the varicella-zoster virus glycoproteins.

C Grose1, V Litwin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834465     DOI: 10.1093/infdis/157.5.877

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.

Authors:  J A Englund; A M Arvin; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

2.  HSV-1 gB and VZV gp-II crossreactive antibodies in human sera.

Authors:  J E Kühn; K Klaffke; K Munk; R W Braun
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

5.  Targeting of glycoprotein I (gE) of varicella-zoster virus to the trans-Golgi network by an AYRV sequence and an acidic amino acid-rich patch in the cytosolic domain of the molecule.

Authors:  Z Zhu; Y Hao; M D Gershon; R T Ambron; A A Gershon
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus.

Authors:  Tae-Young Kang; Hye-Soon Lee; Tae-Hwan Kim; Jae-Bum Jun; Dae-Hyun Yoo
Journal:  Rheumatol Int       Date:  2003-10-31       Impact factor: 3.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.